share_log

Insiders At MiMedx Group Sold US$659k Of Stock Potentially Indicating Weakness

Insiders At MiMedx Group Sold US$659k Of Stock Potentially Indicating Weakness

MiMedx集团内部人士出售65.9万美元的股票,可能表明股价疲软
Simply Wall St ·  2024/11/01 20:45

Despite the fact that MiMedx Group, Inc. (NASDAQ:MDXG) stock rose 17% last week, insiders who sold US$659k worth of stock in the previous 12 months are likely to be better off. Selling at an average price of US$8.02, which is higher than the current price, may have been the best move for these insiders because their investment would have been worth less now than when they sold.

尽管MiMedx集团股票上周上涨了17%,但在过去12个月中卖出价值65.9万美元股票的内部人士很可能更好。以平均价格8.02美元出售,高于当前价格,可能是这些内部人士的最佳选择,因为他们的投资现在的价值比他们出售时更少。

Although we don't think shareholders should simply follow insider transactions, logic dictates you should pay some attention to whether insiders are buying or selling shares.

虽然我们认为股东不应仅仅跟随内部人士的交易,但逻辑告诉我们,应该注意内部人士是购买还是出售股票。

The Last 12 Months Of Insider Transactions At MiMedx Group

过去12个月内部交易MiMedx集团的情况

The insider, Ricci Whitlow, made the biggest insider sale in the last 12 months. That single transaction was for US$250k worth of shares at a price of US$8.06 each. While insider selling is a negative, to us, it is more negative if the shares are sold at a lower price. The silver lining is that this sell-down took place above the latest price (US$6.85). So it may not tell us anything about how insiders feel about the current share price.

在过去12个月中,内部人士中Ricci Whitlow进行了最大规模的内部交易。 单笔交易价值25万美元的股票,每股8.06美元。 尽管内部人士的卖出是负面的,但对我们来说,如果股票以较低价格出售,则更负面。 唯一的好消息是这次股票抛售是在最新价格(6.85美元)之上进行的。 因此,这可能无法告诉我们内部人士对当前股价的感受。

All up, insiders sold more shares in MiMedx Group than they bought, over the last year. The chart below shows insider transactions (by companies and individuals) over the last year. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!

总的来说,在过去一年内,MiMedx集团的内部人员卖出的股票比购买的要多。 下面的图表显示了过去一年中公司和个人的内部交易。 如果您点击图表,可以看到所有个别交易,包括股价、个人和日期!

big
NasdaqCM:MDXG Insider Trading Volume November 1st 2024
纳斯达克CM:mimedx内部交易成交量2024年11月1日

For those who like to find hidden gems this free list of small cap companies with recent insider purchasing, could be just the ticket.

对于那些喜欢发现潜力股票的人,可以免费查看最新内部交易股票的小盘公司名单,这可能正是您要找的机会。

Insider Ownership Of MiMedx Group

mimedx集团内部所有权

Many investors like to check how much of a company is owned by insiders. I reckon it's a good sign if insiders own a significant number of shares in the company. Insiders own 1.4% of MiMedx Group shares, worth about US$14m. This level of insider ownership is good but just short of being particularly stand-out. It certainly does suggest a reasonable degree of alignment.

许多投资者喜欢查看公司由内部所有者拥有多少股份。我认为,如果内部人员在公司中拥有大量股份,这是一个好迹象。内部人员拥有MiMedx集团股份的1.4%,价值约1400万美元。这种内部人员所有权水平很好,但还不足以引人注目。它确实表明了合理程度的一致性。

So What Does This Data Suggest About MiMedx Group Insiders?

这些数据暗示MiMedx集团内部人员有什么?

The fact that there have been no MiMedx Group insider transactions recently certainly doesn't bother us. We don't take much encouragement from the transactions by MiMedx Group insiders. But it's good to see that insiders own shares in the company. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing MiMedx Group. For instance, we've identified 3 warning signs for MiMedx Group (2 shouldn't be ignored) you should be aware of.

最近没有MiMedx集团内部交易的事实确实不会让我们感到不安。我们对MiMedx集团内部人员的交易并不感到鼓舞。但看到内部人员拥有公司的股份是好事。除了了解正在发生的内部交易,识别面临MiMedx集团的风险也是有益的。例如,我们已经发现MiMedx集团存在3个警示信号(2个不应被忽视),您应该注意。

Of course MiMedx Group may not be the best stock to buy. So you may wish to see this free collection of high quality companies.

当然,mimedx集团可能不是最佳的股票买入选择。因此,您可能希望查看这些优质公司的免费收藏。

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

对于本文而言,内部人是指向相关监管机构报告其交易的个人。我们目前仅考虑公开市场交易和直接利益的私人处置,但不包括衍生交易或间接利益。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对本文有任何反馈?对内容有任何疑虑?请直接与我们联系。或者,发送电子邮件至editorial-team@simplywallst.com。
这篇文章是Simply Wall St的一般性文章。我们根据历史数据和分析师预测提供评论,只使用公正的方法论,我们的文章并不意味着提供任何金融建议。文章不构成买卖任何股票的建议,也不考虑您的目标或您的财务状况。我们的目标是带给您基本数据驱动的长期关注分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。Simply Wall St没有任何股票头寸。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发